Implementation and feasibility of DPYD-guided fluoropyrimidine use in a gastrointestinal oncology clinic at an academic medical center
- 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida , , ,
- 2University of Florida Health Cancer Institute , , ,
- 3Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida , , ,
Abstract
Introduction: Genetic variation in DPYD can result in reduced fluoropyrimidine (FP) metabolism and increased risk of severe toxicity. This DPYD test implementation pilot aimed to establish a feasible workflow for DPYD ordering sample collection and FP dose modifications at the University of Florida Health Cancer Institute.
Patients and methods: Following education on the clinical utility of DPYD testing, a consensus was reached with the University of Florida Health gastrointestinal oncology clinic on an implementation workflow. Novel clinical decision support (CDS) tools were developed including pre- and post-test inline warnings in chemotherapy treatment plans, clickable dose modification buttons, and a pharmacist-facing alert upon medication verification. Primary outcomes were feasibility metrics including rates and timing of test ordering and sample collection, genotype turnaround time, and clinician response to CDS tools (e.g., FP dose modifications).
Results: DPYD was ordered for 201 patients between July 2024 and March 2026. Most (180/201) orders were placed prior to chemotherapy in FP-naïve individuals, and 85% (153/180) were also collected pretreatment. The average genotype turnaround time was 5.0 ± 2.7 days. Results were available prior to chemotherapy for 80.3% (114/142) of all patients who received a FP-containing regimen and for 93.2% (110/118) of those with DPYD ordered and collected pretreatment. Nine patients had a deleterious DPYD variant; all who newly initiated a FP-containing regimen received a 50% dose reduction.
Discussion: DPYD test implementation with customized CDS tools to support test ordering and FP prescribing in an academic oncology clinic is feasible, with the majority of results returning prior to chemotherapy. Integrating new and unique processes into already established workflows helps achieve timely test ordering and sample collection.
Related
- Implementation science in global paediatric oncology: a scoping review protocol.
- Academic treatment optimization studies in oncology and internal medicine: a risk- and burden-adapted regulatory framework for the European Union.
- Longitudinal Trajectories of Physical and Mental Health-Related Quality of Life Following Psychobiotic Supplementation in Gastrointestinal Oncology Patients: A Post Hoc Analysis of the ProDeCa Study
- Beyond Manufacturing Feasibility: From Point-of-Care Manufacturing to Point-of-Care Implementation
- FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients
BibTeX
@article{norris2026implementation,
title = {{Implementation and feasibility of DPYD-guided fluoropyrimidine use in a gastrointestinal oncology clinic at an academic medical center}},
author = {Madeline L. Norris and Khoa A. Nguyen and Emily J. Cicali and Wandyeind Marquez Moyeno and Je-Won J. Hong and Katherine Vogel Anderson and Tim Jang and Gahyun Gim and Kathleen Sullivan and Alexandra Kennan and Petr Starostik and Thomas J. George and David L. DeRemer and Larisa H. Cavallari and Julio D. Duarte},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1944703},
url = {https://europepmc.org/article/PMC/PMC13662113},
note = {CC BY},
}
RIS
TY - JOUR
TI - Implementation and feasibility of DPYD-guided fluoropyrimidine use in a gastrointestinal oncology clinic at an academic medical center
AU - Madeline L. Norris
AU - Khoa A. Nguyen
AU - Emily J. Cicali
AU - Wandyeind Marquez Moyeno
AU - Je-Won J. Hong
AU - Katherine Vogel Anderson
AU - Tim Jang
AU - Gahyun Gim
AU - Kathleen Sullivan
AU - Alexandra Kennan
AU - Petr Starostik
AU - Thomas J. George
AU - David L. DeRemer
AU - Larisa H. Cavallari
AU - Julio D. Duarte
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1944703
UR - https://europepmc.org/article/PMC/PMC13662113
AB - Introduction: Genetic variation in DPYD can result in reduced fluoropyrimidine (FP) metabolism and increased risk of severe toxicity. This DPYD test implementation pilot aimed to establish a feasible workflow for DPYD ordering sample collection and FP dose modifications at the University of Florida Health Cancer Institute. Patients and methods: Following education on the clinical utility of DPYD testing, a consensus was reached with the University of Florida Health gastrointestinal oncology clinic on an implementation workflow. Novel clinical decision support (CDS) tools were developed including pre- and post-test inline warnings in chemotherapy treatment plans, clickable dose modification buttons, and a pharmacist-facing alert upon medication verification. Primary outcomes were feasibility metrics including rates and timing of test ordering and sample collection, genotype turnaround time, and clinician response to CDS tools (e.g., FP dose modifications). Results: DPYD was ordered for 201 patients between July 2024 and March 2026. Most (180/201) orders were placed prior to chemotherapy in FP-naïve individuals, and 85% (153/180) were also collected pretreatment. The average genotype turnaround time was 5.0 ± 2.7 days. Results were available prior to chemotherapy for 80.3% (114/142) of all patients who received a FP-containing regimen and for 93.2% (110/118) of those with DPYD ordered and collected pretreatment. Nine patients had a deleterious DPYD variant; all who newly initiated a FP-containing regimen received a 50% dose reduction. Discussion: DPYD test implementation with customized CDS tools to support test ordering and FP prescribing in an academic oncology clinic is feasible, with the majority of results returning prior to chemotherapy. Integrating new and unique processes into already established workflows helps achieve timely test ordering and sample collection.
SN - 2234-943X
ER -